Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one

Mol Cell Oncol. 2014 Dec 31;1(4):e969133. doi: 10.4161/23723548.2014.969133. eCollection Oct-Dec 2014.

Abstract

Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents.

Keywords: HMG-CoA Reductase; Mevalonate; SREBP2; dipyridamole; statins.